PCM
RUBY

Prelude Capital Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Prelude Capital Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-352
Closed -$6K – 2182
2019
Q2 		$6K Buy
+352
New +$5.68K ﹤0.01% 1514

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Prelude Capital Management's RUBY Position: Q3 2019 in Review

Prelude Capital Management sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2019, closing a stake of 352 shares — an estimated $6K sold.

Prelude Capital Management first reported a position in RUBY in Q2 2019 and held it in 1 quarter. The position peaked at $6K in Q2 2019. 75 funds tracked by Wall St. Rank hold RUBY as of Q3 2019.

  • Prelude Capital Management reported no remaining Rubius Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
  • Prelude Capital Management sold 352 Rubius Therapeutics, Inc shares in Q3 2019, an estimated $6K.
  • Prelude Capital Management first reported a position in Rubius Therapeutics, Inc in Q2 2019 and held it in 1 quarter.
  • Prelude Capital Management's Rubius Therapeutics, Inc position peaked at $6K in Q2 2019.
  • 75 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2019.

Based on Prelude Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.